Parnate (tranylcypromine sulfate) NDC 59212-447

NDC codes

FDA NDC Directory

Product NDC (as listed)59212-447Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59212-0447Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59212-447-10	59212044710	100 TABLET, FILM COATED in 1 BOTTLE (59212-447-10)Marketed from Jan 14, 2013

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Parnate
Generic name (nonproprietary): tranylcypromine sulfate
Active ingredients: Tranylcypromine sulfate — 10 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Advanz Pharma (US) Corp.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 012342
Marketing start: Jan 14, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 59212-447_1e311326-d555-4a01-91a5-f53077a450c4SPL ID 1e311326-d555-4a01-91a5-f53077a450c4SPL set ID b72d8187-dfcc-4ea0-b5e9-c0be95b69a27RxCUI 104838, 313447UNII 7ZAT6ES870
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459212044710 followed by a unit qualifier and the quantity

Package 59212-0447-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 2, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

PARNATE is indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. PARNATE is not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [ see Contraindications (4) , Warnings and Precautions (5) , and Drug Interactions (7) ] . PARNATE is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants (1) PARNATE is not indicated for the initial treatment of MDD due to the potential for serious adve…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 012342

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 012342
Product	Strength	Form · route	Labeler	Product NDC
Tranylcypromine Sulfate	Tranylcypromine sulfate 10 mg/1	Tablet, Film coatedOral	Actavis Pharma, Inc.	0591-5590